SLC5A2 and diabetic cardiomyopathy: The study showed that the SGLT2 inhibitor improves the animal condition with diabetic cardiomyopathy by affecting the miR-30d/KLF9/VEGFA pathway, which regulates the expression of autophagy factors protein light chain 3 (LC3-II) and p62/SQSTM1 (p62/sequestosome 1) [219].